Last reviewed · How we verify
Cortisone Injection
Cortisone Injection, marketed by Scott and White Hospital & Clinic, is a well-established treatment in the pharmaceutical market. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the loss of exclusivity post-2028, which could significantly impact revenue.
At a glance
| Generic name | Cortisone Injection |
|---|---|
| Also known as | Steroid injection |
| Sponsor | Scott and White Hospital & Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Conservative Treatment of Trigger Finger (NA)
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- Hoffa's Fat Pad Impingement (HFPI) (PHASE4)
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (PHASE3)
- REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial (PHASE3)
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (PHASE2)
- Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cortisone Injection CI brief — competitive landscape report
- Cortisone Injection updates RSS · CI watch RSS
- Scott and White Hospital & Clinic portfolio CI